| RA (N=25) | Controls (N=25) | P value |
---|
|
---|
Female (N/%) | 23/92 | 23/92 | N.S. |
Age (years) | 65.4±11.5 | 60.1±9.3 | N.S. |
Disease duration (years) | 13±8.2 | N.A. | N.A. |
DAS28 | 6.5±1.3 | N.A. | N.A. |
HAQ | 1.9±0.8 | N.A. | N.A. |
Positivity of RF (N/%) | 17/68 | N.A. | N.A. |
Positivity of ACPA (N/%) | 20/80 | N.A. | N.A. |
ESR (mm/h) | 58±28 | N.A. | N.A. |
CRP (mg/l) | 8.5±7.6 | N.A. | N.A. |
C3 (mg/dl) | 119.4±22.4 | 104±18 | 0.04 |
C4 (mg/dl) | 26±6.7 | 22±4 | 0.013 |
CH50 (%) | 108±24 | 100±18 | N.S. |
Therapy: | | N.A. | |
PDN ≤7.5 mg/die (N/%) | 9/36 | | |
At least one DMARD (N/%) | 13/52 | | |
– MTX (N/%) | 9/69.2 | | |
– HCQ (N/%) | 4/30.7 | | |
– SSZ (N/%) | 2/15.4 | | |
– LEF (N/%) | 2/15.4 | | |
I line TCZ (N/%) | 3/12 | | |
II line TCZ (N/%) | 3/12 | | |
III line TCZ (N/%) | 9/36 | | |
IV line TCZ (N/%) | 7/28 | | |
V line TCZ (N/%) | 3/12 | | |